Best response according to treatment phase (intention-to-treat analysis)
| . | PAD (n = 102) . | PAD-MEL100-ASCT (n = 102) . | PAD-MEL100-ASCT-LP (n = 102) . | PAD-MEL100-ASCT-LP-L (n = 102) . |
|---|---|---|---|---|
| CR or VGPR | 56 (55%) | 78 (76%) | 82 (80%) | 84 (82%) |
| CR | 12 (12%) | 34 (33%) | 49 (48%) | 54 (53%) |
| VGPR | 44 (43%) | 44 (43%) | 33 (32%) | 30 (29%) |
| PR | 34 (33%) | 17 (17%) | 14 (14%) | 13 (13%) |
| SD | 11 (11%) | 6 (6%) | 5 (5%) | 4 (4%) |
| PD | 0 | 0 | 0 | 0 |
| NA | 1 (1%) | 1 (1%) | 1 (1%) | 1 (1%) |
| . | PAD (n = 102) . | PAD-MEL100-ASCT (n = 102) . | PAD-MEL100-ASCT-LP (n = 102) . | PAD-MEL100-ASCT-LP-L (n = 102) . |
|---|---|---|---|---|
| CR or VGPR | 56 (55%) | 78 (76%) | 82 (80%) | 84 (82%) |
| CR | 12 (12%) | 34 (33%) | 49 (48%) | 54 (53%) |
| VGPR | 44 (43%) | 44 (43%) | 33 (32%) | 30 (29%) |
| PR | 34 (33%) | 17 (17%) | 14 (14%) | 13 (13%) |
| SD | 11 (11%) | 6 (6%) | 5 (5%) | 4 (4%) |
| PD | 0 | 0 | 0 | 0 |
| NA | 1 (1%) | 1 (1%) | 1 (1%) | 1 (1%) |
Percentage may not total 100 because of rounding.
NA, not available; SD, stable disease.